Published in Br J Haematol on May 01, 2004
Rituximab for steroid-refractory chronic graft-versus-host disease. Blood (2006) 3.08
Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study. Blood (2010) 2.34
High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res (2007) 2.00
Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease. Blood (2007) 1.96
Emergent autoimmunity in graft-versus-host disease. Blood (2005) 1.37
Chronic graft-versus-host disease (GVHD) in children. Pediatr Clin North Am (2010) 0.94
Extracorporeal Photochemotherapy as a Challenging Treatment for Cutaneous T-Cell Lymphoma, Acute and Chronic Graft-versus-Host Disease, Organ Rejection and T-Lymphocyte-Mediated Autoimmune Diseases. Transfus Med Hemother (2007) 0.91
Identification of stem cell transcriptional programs normally expressed in embryonic and neural stem cells in alloreactive CD8+ T cells mediating graft-versus-host disease. Biol Blood Marrow Transplant (2010) 0.88
Guidelines on the use of extracorporeal photopheresis. J Eur Acad Dermatol Venereol (2014) 0.85
Hematopoietic stem cell transplantation. Stem Cells Cloning (2010) 0.84
A multicenter feasibility study of chronic graft-versus-host disease according to the National Institute of Health criteria: efforts to establish a Brazil-Seattle consortium as a platform for future collaboration in clinical trials. Rev Bras Hematol Hemoter (2011) 0.83
High incidence of herpes zoster in nonmyeloablative hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2010) 0.82
Ocular manifestations of graft-versus-host disease. Saudi J Ophthalmol (2013) 0.77
Chronic Graft Versus Host Disease in Acute Leukemia Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant: Analysis of Risk Factors, Pattern and Long Term Outcome. Indian J Hematol Blood Transfus (2015) 0.75
Epidermal elafin expression is an indicator of poor prognosis in cutaneous graft-versus-host disease. J Invest Dermatol (2014) 0.75
Membranous nephropathy and lupus-like syndrome after hematopoietic cell transplantation: a case report. J Med Case Rep (2010) 0.75
The Relationship between STR-PCR Chimerism Analysis and Chronic GvHD Following Hematopoietic Stem Cell Transplantation. Int J Hematol Oncol Stem Cell Res (2017) 0.75
Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review. Clin Rev Allergy Immunol (2017) 0.75
Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant (2006) 4.09
Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biol Blood Marrow Transplant (2006) 2.63
Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant (2006) 2.44
Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. Blood (2011) 2.26
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report. Biol Blood Marrow Transplant (2006) 2.24
Association of Foxp3 regulatory gene expression with graft-versus-host disease. Blood (2004) 2.20
Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report. Biol Blood Marrow Transplant (2006) 1.86
Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant (2010) 1.69
A multicenter pilot evaluation of the National Institutes of Health chronic graft-versus-host disease (cGVHD) therapeutic response measures: feasibility, interrater reliability, and minimum detectable change. Biol Blood Marrow Transplant (2011) 1.54
Validation of measurement scales in ocular graft-versus-host disease. Ophthalmology (2011) 1.50
Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. Biol Blood Marrow Transplant (2010) 1.34
Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. Biol Blood Marrow Transplant (2010) 1.33
Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study. Blood (2003) 1.29
Phase II study of pentostatin in patients with corticosteroid-refractory chronic graft-versus-host disease. J Clin Oncol (2007) 1.27
Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biol Blood Marrow Transplant (2002) 1.27
Stem cell transplantation: supportive care and long-term complications. Hematology Am Soc Hematol Educ Program (2002) 1.24
Pentostatin in steroid-refractory acute graft-versus-host disease. J Clin Oncol (2005) 1.15
Acute graft versus host disease. Orphanet J Rare Dis (2007) 1.12
Clinical benefit of response in chronic graft-versus-host disease. Biol Blood Marrow Transplant (2012) 1.10
Hepatitic variant of graft-versus-host disease after donor lymphocyte infusion. Blood (2002) 1.10
Infliximab for steroid-refractory acute GVHD: a case series. Am J Hematol (2003) 1.06
Assessment of joint and fascia manifestations in chronic graft-versus-host disease. Arthritis Rheumatol (2014) 1.04
Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions. Biol Blood Marrow Transplant (2006) 0.99
Gastrointestinal involvement in chronic graft-versus-host disease: a clinicopathologic study. Biol Blood Marrow Transplant (2003) 0.97
Myxedema ascites in the posttransplant setting: case report. Am J Hematol (2002) 0.94
Novel strategies for steroid-refractory acute graft-versus-host disease. Curr Opin Hematol (2005) 0.93
Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells. Biol Blood Marrow Transplant (2003) 0.89
Chronic Graft-versus-Host Disease--implementation of the National Institutes of Health Consensus Criteria for Clinical Trials. Biol Blood Marrow Transplant (2008) 0.89
Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma. Biol Blood Marrow Transplant (2007) 0.88
A systematic approach to hepatic complications in hematopoietic stem cell transplantation. J Hematother Stem Cell Res (2002) 0.87
Acute graft-versus-host disease. Clin Adv Hematol Oncol (2004) 0.86
Gastrointestinal toxicity from the preparative regimen is associated with an increased risk of graft-versus-host disease. Biol Blood Marrow Transplant (2005) 0.85
Anti-cytokine therapy for the treatment of graft-versus-host disease. Curr Pharm Des (2004) 0.84
The effects of interleukin 10 and interferon gamma cytokine gene polymorphisms on survival after autologous bone marrow transplantation for patients with breast cancer. Biol Blood Marrow Transplant (2005) 0.83
Acute bleeding complications in patients after hematopoietic stem cell transplantation with prophylactic platelet transfusion triggers of 10 x 10(9) and 20 x 10(9) per L. Transfusion (2007) 0.83
Evaluation of pentostatin in corticosteroid-refractory chronic graft-versus-host disease in children: a Pediatric Blood and Marrow Transplant Consortium study. Blood (2009) 0.83
Profound thrombocytopenia and survival of hematopoietic stem cell transplant patients without clinically significant bleeding, using prophylactic platelet transfusion triggers of 10 x 10(9) or 20 x 10(9) per L. Transfusion (2007) 0.82
Wasted sheep and premature infants: the role of trace metals in hematopoiesis. Blood Rev (2004) 0.80
Lymphocytic pneumonitis as the manifestation of acute graft-versus-host disease of the lung. Am J Hematol (2005) 0.80
Novel pharmacotherapeutic approaches to prevention and treatment of GVHD. Drugs (2002) 0.79
Grover's Disease after Bone Marrow Transplantation. Biol Blood Marrow Transplant (2007) 0.79
Autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide purging for acute myeloid leukaemia beyond first remission: a 10-year experience. Br J Haematol (2002) 0.79
Pentostatin - pharmacology, immunology, and clinical effects in graft-versus-host disease. Expert Opin Pharmacother (2004) 0.79
Chronic graft-versus-host disease. Curr Pharm Des (2008) 0.78
Pentostatin for the treatment of chronic graft-versus-host disease in children. J Pediatr Hematol Oncol (2003) 0.78
Hepatic venoocclusive disease in blood and bone marrow transplantation in children: incidence, risk factors, and outcome. J Pediatr Hematol Oncol (2002) 0.78
Mesenchymal stem cells and organ transplantation: current status and promising future. Transplantation (2006) 0.77
Montelukast in chronic graft-versus-host disease: a breath of fresh air? Transplantation (2007) 0.75
Rapid engraftment at a cost? Transplantation (2010) 0.75
Keeping up with Blood: introducing our CME program. Blood (2010) 0.75